Leveraging Single-Cell Multi-Omic Analytical Assays to Accelerate Advanced Therapeutics Development

by | May 17, 2021 | News, NGS, Single Cell


Leveraging Single-Cell Multi-Omic Analytical Assays to Accelerate Advanced Therapeutics Development

As a pioneer in high-throughput single-cell multi-omic analysis, Mission Bio has developed a platform to genotype and phenotype from the same cell.

During the webinar we will share:

  • Cell & Gene Therapy
  • Featuring guest speaker Jenny Xiao (Illumina)


25 May 2021, Tuesday

09:00 am – 10:15 am (Hong Kong / Singapore)

We understand that our chosen timing may not suit your busy schedule. Please feel free to register to get the on-demand recording link once it is ready.

This presentation will begin on Tuesday, 25 May 2021 at 09:00 AM Hong Kong Time.

Audience members may arrive 15 minutes in advance of this time.

Matt Cato

Director, Cell and Gene Therapy @Mission Bio
Matthew Cato is a business and market development leader who specializes in cell and gene therapies and precision medicine. With a background in immunology and biotechnology, he focuses on strategic commercial development for single-cell technology to advance cell and gene therapeutic solutions.

Jenny Xiao

Associate Director, Emerging Technologies @Illumina
Jenny Xiao is Associate Director, Emerging Market, for NGS genomic applications at Illumina. She currently focuses on developing KOL relationships and scientific society engagements in the field of Gene editing, Single cell, Spatial, and Proteomics. Examples include participating NIST (National institute of standard and technology) genome editing consortium to develop standard control samples and off-target validation procedure for gene editing based cell and gene therapies. Jenny completed her BS in Biology at Peking University, MBA at Santa Clara University and Ph.D. in Entomology at University of Hawaii at Manoa. After her postdoctoral training at Stanford Medical School, Jenny held different technical and commercial roles at Agilent Technologies, Agena, and Thermo Fisher Scientific with leading genomic technologies, including microarray, Mass-spec, real-time PCR, Sanger Sequencing, and NGS.

Ready to build your DNA + Protein panel?

Chat with one of our design experts to build a panel to simultaneously detect SNVs, CNVs, and protein expression.

Share This